OnCusp Therapeutics appoints CMO

24 June 2025

New Jersey, USA-based clinical-stage biotech OnCusp Therapeutics has announced the appointment of Dr Dimitry Nuyten as chief medical officer (CMO).

Dr Nuyten is a seasoned oncology drug development executive with over 17 years of experience leading global clinical programs from first-in-human studies to regulatory approvals. At OnCusp, he will lead clinical strategy and execution, leveraging his deep expertise to advance the company’s lead Cadherin-6 (CDH6)-targeting antibody-drug conjugate (ADC) program, CUSP06, through clinical development. He will report to OnCusp’s chief executive Bing Yuan,

“Dr Nuyten brings extensive experience in oncology drug development and a strong track record of leadership across both biotech and large pharma,” said Dr Yuan. “He is an outstanding addition to the OnCusp executive team, and his success advancing innovative therapies, including ADCs and immuno-oncology agents, will be instrumental as we progress CUSP06’scclinical development and seek meaningful outcomes for patients,” he added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK